Posters

3 year results after the implantation of the microstent cypass

Poster Details

First Author: M.Rau GERMANY

Co Author(s):                  

Abstract Details

Purpose:

To evaluate the safety and clinical outcomes of an ab interno supraciliary implant (CyPass Micro-Stent, Transcend Medical, Inc., Menlo Park, CA, USA) in patients with open-angle glaucoma (OAG) undergoing cataract surgery or as a standalone procedure.

Setting:

eye clinic Cham, Janahof 2, 93413 Cham, Germany

Methods:

33 Eyes were enrolled in the study. 24 eyes were undergoing concomitant cataract surgery. The supraciliary device was implanted immediately following the cataract surgery portion of the procedure through the same corneal incision using an ab interno approach. Medications were stopped following the procedure and re-introduced depending on the intraocular pressure (IOP) target of the patient. After 3 years the position of the cypass in iridocorneal angle was observed with goniolens and documented with slip lamp photo. The effect was examined in assessment of the number of IOL reduction and number of the IOP-lowering medications.

Results:

The position of cypass in iridocorneal angle after three years was stable, there was no migration, no obstruction. In one case the adherence of iris to the cypass occurred, which could be successfully treated with Yag Laser. At 36 months there is in comparism to baseline still a reduction of IOP and the number of used medication, but slight elevation in comparison to 12 months.

Conclusions:

As a micro invasive procedure for OAG, the CyPass implantation combined with cataract surgery or as stand alone procedure was associated with stable position in iridocorneal angle and effective at significantly lowering IOP and IOP-lowering medication use at three years. FINANCIAL DISCLOUSRE: One or more of the authors research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented